Literature DB >> 2671265

Neoplastic meningitis in malignant melanoma: diagnosis with monoclonal antibodies.

R P Moseley1, A G Davies, S P Bourne, C Popham, S Carrel, P Monro, H B Coakham.   

Abstract

Six patients with neoplastic melanomatous meningitis were studied. The diagnosis of this complication of malignant disease rests on the demonstration of malignant cells within the CSF. The addition of monoclonal antibody immunocytology to conventional techniques significantly improved the diagnostic sensitivity of CSF cytology, allowing for earlier and therefore more effective palliative treatment.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2671265      PMCID： PMC1031937          DOI： 10.1136/jnnp.52.7.881

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  22 in total

1.  Use of monoclonal antibody panel to identify malignant cells in cerebrospinal fluid.

Authors:  H B Coakham; J A Garson; B Brownell; P M Allan; E I Harper; E B Lane; J T Kemshead
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

2.  Production and characterization of monoclonal antibody to a melanoma specific glycoprotein.

Authors:  A C Morgan; D R Galloway; R A Reisfeld
Journal:  Hybridoma       Date:  1981

3.  Immunohistochemical demonstration of vimentin in human cerebral tumors.

Authors:  D Schiffer; M T Giordana; A Mauro; A Migheli; I Germano; G Giaccone
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

4.  The present role of monoclonal antibodies in the diagnosis and therapy of brain tumours.

Authors:  H B Coakham; J T Kemshead
Journal:  Wien Klin Wochenschr       Date:  1987-05-29       Impact factor: 1.704

5.  Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application.

Authors:  T Nakajima; S Watanabe; Y Sato; T Kameya; Y Shimosato; K Ishihara
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

6.  Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3.

Authors:  C Vennegoor; J Calafat; P Hageman; F van Buitenen; H Janssen; A Kolk; P Rümke
Journal:  Int J Cancer       Date:  1985-03-15       Impact factor: 7.396

7.  The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology.

Authors:  J A Garson; H B Coakham; J T Kemshead; B Brownell; E I Harper; P Allan; S Bourne
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Vimentin: an evaluation of its role as a tumour marker.

Authors:  M Leader; M Collins; J Patel; K Henry
Journal:  Histopathology       Date:  1987-01       Impact factor: 5.087

9.  Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions.

Authors:  R M Mackie; I Campbell; M L Turbitt
Journal:  J Clin Pathol       Date:  1984-04       Impact factor: 3.411

10.  Monoclonal antibodies provide specific intramolecular markers for the study of epithelial tonofilament organization.

Authors:  E B Lane
Journal:  J Cell Biol       Date:  1982-03       Impact factor: 10.539
View more
  2 in total

1.  Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis.

Authors:  Emilie Le Rhun; Qian Tu; Marcelo De Carvalho Bittencourt; Isabelle Farre; Laurent Mortier; Huili Cai; Chantal Kohler; Gilbert C Faure
Journal:  Med Oncol       Date:  2013-03-16       Impact factor: 3.064

2.  Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options.

Authors:  Carlos R Goulart; Tobias Alecio Mattei; Ricardo Ramina
Journal:  ISRN Surg       Date:  2011-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.